Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort - Itamochi, Masae; Yazawa, Shunsuke; Inasaki, Noriko; Saga, Yumiko; Yamazaki, Emiko; Shimada, Takahisa; Tamura, Kosuke; Maenishi, Emi; Isobe, Junko; Nakamura, Masahiko; Takaoka, Misuzu; Sasajima, Hitoshi; et al. (Vaccine, 2023)
Keywords: Adult; Adults; Aged; Aged, 80 and over; Allergy and Immunology; Antibodies, Neutralizing; Antibodies, Viral; blood serum; BNT162 Vaccine; cohort studies; Coronaviruses; COVID-19; COVID-19 - prevention & control; COVID-19 infection; COVID-19 vaccines; COVID-19 Vaccines - administration & dosage; domain; East Asian People; Enzymes; Epidemics; Genomes; Humans; Immunization, Secondary; Immunogenicity; Immunoglobulin G; Infections; Mortality; mRNA; mRNA vaccine; mRNA vaccines; Neutralization; Neutralizing antibody; nucleocapsid; Nucleocapsids; Nursing Homes; Older adults; Older people; Omicron subvariants; Prospective Studies; Proteins; Pseudotyped virus; risk; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; vaccination; Vaccines; Viral diseases; Viruses; United States--US; Japan; Germany; N protein; SARS-CoV-2pv; LTCF; Omicron subvariants; Older adults; Neutralizing antibody; COVID-19; Pseudotyped virus; SARS-CoV-2; VSVs; S; RBD; BTI; NGS; mRNA vaccine; ELISA; vesicular stomatitis virus; spike; severe acute respiratory syndrome coronavirus 2; breakthrough infection; nucleocapsid protein, NT, neutralizing titer; severe acute respiratory syndrome coronavirus 2 pseudotyped virus; next-generation sequencing; receptor-binding domain; long-term care facility; coronavirus disease 2019; enzyme-linked immunosorbent assay